Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label comparison of semaglutide injection versus Novo Nordisk's semaglutide brand in adults with type 2 diabetes mellitus on stable metformin
CTR20252373Phase 3Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shandong New Era Pharmaceutical. Primary endpoint: Change in HbA1c from baseline at week 32. Started Sep 2025; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252373.